实时全球研报
Feedback from Follow-up on New Mid-term Plan
研报英文原文证据摘录
Feedback from Follow-up on New Mid-term Plan
Update
July 20, 2026 10:20 AM GMT
Morgan Stanley MUFG Securities Co., Ltd.+MShimadzu (7701) | Japan Mie Yamazaki
Equity Analyst
Feedback from Follow-up on Mie.Yamazaki@morganstanleymufg.comKazuo Yoshikawa, CFA +81 3 6836-8899
Kazuo.Yoshikawa@morganstanleymufg.com +81 3 6836-8408
New Mid-term Plan Hidetaka Suzuki
Research Associate
Hidetaka.Suzuki@morganstanleymufg.com +81 3 6836-8402
Key Takeaways
We followed up with Shimadzu on its new mid-term plan (unveiled Jun 4).
We confirmed steps it will take to achieve the plan's KPI targets. In measuring
instruments the main point is likely to be improving margins via price adjustment,
whose effects are likely to take time to establish. Shimadzu (7701.T, 7701 JT)
Precision Instruments | Japan
The move into the semis inspection field via Tescan has potential to boost
Stock Rating Underweight
multiples, but we have the impression of considerable challenges in areas Industry View In-Line
including near-line uptake, and will be watching outcomes as they emerge. Price target ¥3,400
Shr price, close (Jul 17, 2026) ¥4,180
Mkt cap, curr, basic (bn) ¥1,207.6
MTP themes & key measures: The latest mid-term plan (F3/27-29) puts an Avg daily trading value (bn) ¥4.8
emphasis on improving earnings capability. In measuring instruments business, the
firm will continue to put efforts into strengthening its position in the clinical trials
field. By bringing Tescan into the fold, it also aims to extend business in the growing
semiconductors field. In terms of earnings, it expects a pickup in the 2nd half of the
plan. Drivers of improved operating margins in measuring instruments (+3.1ppt vs.
F3/26) are to be expansion of new product sales and price revisions in existing
businesses.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器